https://www.ispor.org/vih-articles/Volume-13--Issue-7/PCN44-COST-COMPARISON-OF-ERLOTINIB-VERSUS-PEMETREXED-FOR-THE-FIRST-LINE-MAINTENANCE-TREATMENT-OF-PATIENTS-WITH-LOCALLY-ADVANCED-OR-METASTATIC-NON-SMALL-CELL-LUNG-CANCER-IN-SPAIN
PCN44 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF...